Equillium (EQ)

Market Price (9/7/2026): $2.2 | Market Cap: $246.0 MilSector: Health Care | Industry: Biotechnology

Equillium (EQ)

Market Price (9/7/2026): $2.2
Market Cap: $246.0 Mil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -23%

Megatrend and thematic drivers
Megatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more.

Very low revenue
Rev LTMTotal Revenue or Sales, Last Twelve Months is 0

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -19 Mil

Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is null, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -45%

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -12%

High stock price volatility
Vol 12M is 105%

Key risks
EQ key risks include [1] significant regulatory uncertainty for its lead drug itolizumab after the FDA declined to support an accelerated approval pathway, Show more.

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -23%
1	Megatrend and thematic drivers Megatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more.
2	Very low revenue Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
3	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -19 Mil
4	Weak revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is null, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -45%
5	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -12%
6	High stock price volatility Vol 12M is 105%
7	Key risks EQ key risks include [1] significant regulatory uncertainty for its lead drug itolizumab after the FDA declined to support an accelerated approval pathway, Show more.

EQ in ETFs

Weight = EQ's share of each fund

VTI0.00%

DFAS0.00%

Valuation & Metrics

FYE: 12/31	Forward FYE		Now	Historical (CYE & TTM)
	2027	2026	9/7/26	2025	2024	2023	2022
Share Price			$2.20	$1.55	$0.75	$0.72	$1.06
Mkt Cap ($ Mil)			246.0	95.3	26.5	25.4	36.4
+ Debt ($ Mil)			0.6	0.7	0.4	0.8	10.2
- Cash ($ Mil)			57.2	30.3	22.6	40.9	71.0
TEV ($ Mil)			189.4	96.0	26.9	26.2	46.6
Valuation Ratios
P/S	14.9	15.8	-	-	0.6	0.7	2.3
P/EBIT	—	—	-12.7	-4.0	-3.2	-2.1	-0.6
P/E	—	—	-13.7	-4.3	-3.3	-1.9	-0.6
P/FCF	—	—	-12.2	-4.2	-1.4	-1.2	-4.0
Sector Ratios (* = sector average)
P/S *			4.3	4.0	3.8	4.2	4.5
P/EBIT *			-2.1	-1.7	-1.4	-1.5	-1.2
P/E *			-2.0	-1.8	-1.6	-1.7	-1.3
P/FCF *			-2.1	-1.7	-1.4	-1.6	-1.5

FYE: 12/31	Forward FYE		Now
	2027	2026	9/7/26
Share Price			$2.20
Mkt Cap ($ Mil)			246.0
+ Debt ($ Mil)			0.6
- Cash ($ Mil)			57.2
TEV ($ Mil)			189.4
Valuation Ratios
P/S	14.9	15.8	-
P/EBIT	—	—	-12.7
P/E	—	—	-13.7
P/FCF	—	—	-12.2
Sector Ratios (* = sector average)
P/S *			4.3
P/EBIT *			-2.1
P/E *			-2.0
P/FCF *			-2.1

FYE: 12/31	EQ [1]	S&P 500 [2]
REVENUE GROWTH
LTM Revenue [3]	$0.0 Mil	—
FY 2026 Sales	$15.6 Mil	—
FY 2027 Sales	$16.5 Mil	—
FY 2026 Sales Growth	—	—
FY 2027 Sales Growth	6.1%	13.2%
EARNINGS
LTM Net Income (GAAP) [3]	$-18.0 Mil	—
FY 2026 Net Income (Non-GAAP)	$-18.4 Mil	—
FY 2027 Net Income (Non-GAAP)	$-24.5 Mil	—
FY 2027 Net Income Growth	—	18.6%
FY 2026 EPS (Non-GAAP)	$-0.20	—
FY 2027 EPS (Non-GAAP)	$-0.23	—
FY 2027 EPS Growth	—	—
VALUATION
FY 2026 P/S	15.8	1.7
FY 2027 P/S	14.9	—
FY 2026 P/E	—	7.7
FY 2027 P/E	—	—

[1] EQ forward figures are analyst consensus for the next two fiscal years (fiscal year end 12/31). Net Income and EPS are non-GAAP (adjusted) consensus. P/S and P/E divide the current market cap by the consensus figure.
[2] S&P 500 figures are the SPY ETF's holdings-weighted forward aggregate. P/S and P/E reflect FY1/FY2 consensus blended to the 12-month window ending 9/30/27 (~one year forward), shown when ≥90% of index weight has estimates. Growth is the aggregate next-fiscal-year vs current-fiscal-year (FY1→FY2) change. Index-level dollar Sales, Net Income and EPS are not applicable.
[3] LTM = reported trailing-twelve-month actuals (GAAP).

null

AI Analysis | Feedback

Metric	Value	Date	Source
Number of Clinical-Stage Drug Candidates	4	11132024	Link
Number of Pre-Clinical-Stage Drug Candidates	1	11132024	Link
Number of Active Clinical Trials	2	11132024	Link
Total Issued U.S. Patents	9	3232023	Link
Total Issued Foreign Patents	45	3232023	Link

Price Chart

null

Recent
8/13/2026	Earnings Release	Rev: - EPS: -
Upcoming
11/12/2026	Earnings Release	Rev: - EPS: -

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Updated on 9/1/2026

Equillium (EQ) stock has lost about 25% since 5/31/2026 because of the following key factors:

1. Lack of Near-Term Positive Clinical Catalysts.

Equillium, as a clinical-stage biotechnology company, relies heavily on significant clinical trial advancements and data readouts. During the period since May 31, 2026, the company's primary pipeline updates centered on future events rather than immediate positive results. The initiation of a Phase 1 proof-of-mechanism study for EQ504, a lead candidate for ulcerative colitis and inflammatory lung diseases, is anticipated in fiscal Q4 2026, with topline data expected approximately six months thereafter. The absence of concrete, positive clinical data or regulatory milestones within fiscal Q2 and early fiscal Q3 2026 likely dampened investor enthusiasm and contributed to a downward re-evaluation of the stock's near-term prospects.

2. Persistent Net Losses.

For the second quarter of fiscal 2026, which ended on June 30, 2026, Equillium reported a net loss of $4.7 million, or $(0.04) per basic and diluted share. Although this result beat the consensus earnings per share estimate of $(0.05) by $0.01, the company continues to operate at a loss. Analysts project a further decrease in earnings for fiscal 2027, with estimates ranging from ($0.21) to ($0.24) per share. This sustained unprofitability can weigh on investor confidence, particularly for growth-oriented biotechnology firms that require significant capital investment without immediate revenue generation.

Show more

Holding a concentrated position? Know your true downside before the momentum shifts.

Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The -23.8% change in EQ stock from 5/31/2026 to 9/6/2026 was primarily driven by a -13.9% change in the company's Shares Outstanding (Mil).

(LTM values as of)	5312026	9062026	Change
Stock Price ($)	2.90	2.21	-23.8%
Change Contribution By:
Total Revenues ($ Mil)	0	0	0.0%
P/S Multiple	∞	∞	0.0%
Shares Outstanding (Mil)	96	112	-13.9%
Cumulative Contribution			0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

5/31/2026 to 9/6/2026

	Return	Correlation
EQ	-23.8%
Market (SPY)	1.8%	5.6%
Sector (XLV)	14.7%	-9.0%

Fundamental Drivers

The 21.4% change in EQ stock from 2/28/2026 to 9/6/2026 was primarily driven by a 9.2233720368547763E17% change in the company's P/S Multiple.

(LTM values as of)	2282026	9062026	Change
Stock Price ($)	1.82	2.21	21.4%
Change Contribution By:
Total Revenues ($ Mil)	4	0
P/S Multiple	27.1	∞	9.2233720368547763E17%
Shares Outstanding (Mil)	65	112	-41.6%
Cumulative Contribution			0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

2/28/2026 to 9/6/2026

	Return	Correlation
EQ	21.4%
Market (SPY)	12.6%	20.9%
Sector (XLV)	7.5%	3.4%

Fundamental Drivers

The 27.0% change in EQ stock from 8/31/2025 to 9/6/2026 was primarily driven by a 9.2233720368547763E17% change in the company's P/S Multiple.

(LTM values as of)	8312025	9062026	Change
Stock Price ($)	1.74	2.21	27.0%
Change Contribution By:
Total Revenues ($ Mil)	17	0
P/S Multiple	3.8	∞	9.2233720368547763E17%
Shares Outstanding (Mil)	36	112	-68.1%
Cumulative Contribution			0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

8/31/2025 to 9/6/2026

	Return	Correlation
EQ	27.0%
Market (SPY)	20.4%	15.8%
Sector (XLV)	26.4%	3.8%

Fundamental Drivers

The 172.8% change in EQ stock from 8/31/2023 to 9/6/2026 was primarily driven by a 9.2233720368547763E17% change in the company's P/S Multiple.

(LTM values as of)	8312023	9062026	Change
Stock Price ($)	0.81	2.21	172.8%
Change Contribution By:
Total Revenues ($ Mil)	34	0
P/S Multiple	0.8	∞	9.2233720368547763E17%
Shares Outstanding (Mil)	34	112	-69.2%
Cumulative Contribution			0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

8/31/2023 to 9/6/2026

	Return	Correlation
EQ	172.8%
Market (SPY)	77.1%	9.8%
Sector (XLV)	34.7%	7.1%

Return vs. Risk

Price Returns Compared

	2021	2022	2023	2024	2025	2026	Total [1]
Returns
EQ Return	-30%	-72%	-32%	3%	107%	43%	-59%
Peers Return	-7%	32%	41%	-1%	13%	12%	114%
S&P 500 Return	27%	-19%	24%	23%	16%	13%	106%
Monthly Win Rates [3]
EQ Win Rate	50%	33%	42%	50%	42%	67%
Peers Win Rate	42%	67%	58%	50%	83%	67%
S&P 500 Win Rate	75%	42%	67%	75%	67%	56%
Max Drawdowns [4]
EQ Max Drawdown	-64%	-80%	-62%	-80%	-69%	-37%
Peers Max Drawdown	-27%	-19%	-12%	-23%	-29%	-15%
S&P 500 Max Drawdown	-5%	-25%	-10%	-8%	-19%	-9%

[1] Cumulative total returns since the beginning of 2021
[2] Peers: VRTX, APMD, ATTO, BLSM, BRVE.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 9/4/2026 (YTD)

Event	EQ	S&P 500
2025 US Tariff Shock
% Loss	-61.5%	-18.8%
% Gain to Breakeven	160.0%	23.1%
Time to Breakeven	75 days	79 days
2024 Yen Carry Trade Unwind
% Loss	-13.2%	-7.8%
% Gain to Breakeven	15.2%	8.5%
Time to Breakeven	2 days	18 days
Summer-Fall 2023 Five Percent Yield Shock
% Loss	-36.1%	-9.5%
% Gain to Breakeven	56.4%	10.5%
Time to Breakeven	55 days	24 days
2023 SVB Regional Banking Crisis
% Loss	-57.1%	-6.7%
% Gain to Breakeven	132.9%	7.1%
Time to Breakeven	273 days	31 days
2020 COVID-19 Crash
% Loss	-54.3%	-33.7%
% Gain to Breakeven	118.7%	50.9%
Time to Breakeven	111 days	140 days
Q4 2018 Fed Policy Error / Growth Scare
% Loss	-54.9%	-19.2%
% Gain to Breakeven	121.5%	23.8%
Time to Breakeven	571 days	105 days

Compare to VRTX, APMD, ATTO, BLSM, BRVE

In The Past

Equillium's stock fell -61.5% during the 2025 US Tariff Shock. Such a loss loss requires a 160.0% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

Event	EQ	S&P 500
2025 US Tariff Shock
% Loss	-61.5%	-18.8%
% Gain to Breakeven	160.0%	23.1%
Time to Breakeven	75 days	79 days
Summer-Fall 2023 Five Percent Yield Shock
% Loss	-36.1%	-9.5%
% Gain to Breakeven	56.4%	10.5%
Time to Breakeven	55 days	24 days
2023 SVB Regional Banking Crisis
% Loss	-57.1%	-6.7%
% Gain to Breakeven	132.9%	7.1%
Time to Breakeven	273 days	31 days
2020 COVID-19 Crash
% Loss	-54.3%	-33.7%
% Gain to Breakeven	118.7%	50.9%
Time to Breakeven	111 days	140 days
Q4 2018 Fed Policy Error / Growth Scare
% Loss	-54.9%	-19.2%
% Gain to Breakeven	121.5%	23.8%
Time to Breakeven	571 days	105 days

Compare to VRTX, APMD, ATTO, BLSM, BRVE

In The Past

Equillium's stock fell -61.5% during the 2025 US Tariff Shock. Such a loss loss requires a 160.0% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Equillium (EQ)

Business Description Analogies Products Customers Suppliers Management Key Risks Emerging Threats Market Size Revenue Drivers Capital Allocation

Equillium, Inc. (EQ) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments for severe autoimmune and inflammatory (immuno-inflammatory) disorders that currently have significant unmet medical needs. As a biotech in the development phase, the company's business primarily revolves around the research, development, and clinical testing of its drug candidates, rather than the sale of approved commercial products.

The company's lead product candidate is itolizumab (EQ001), a monoclonal antibody designed to target the CD6 immune checkpoint receptor. Itolizumab is currently in a Phase III clinical trial for acute graft-versus-host disease (aGVHD), a serious complication of stem cell transplantation. Additionally, it has completed Phase Ib clinical trials for the treatment of asthma and lupus nephritis. Equillium's pipeline also includes EQ101, which is being developed for conditions such as cutaneous T cell lymphoma and alopecia areata, and EQ102, targeting various gastrointestinal diseases, all aimed at serving patient populations impacted by these severe autoimmune and inflammatory conditions.

AI Analysis | Feedback

Here are 1-3 brief analogies to describe Equillium:

A clinical-stage Biogen for severe autoimmune and inflammatory disorders.
Like Vertex Pharmaceuticals, but focused on developing novel therapies for autoimmune and inflammatory conditions.
A Moderna focused on pioneering antibody treatments for autoimmune diseases.

AI Analysis | Feedback

itolizumab (EQ001): A clinical-stage monoclonal antibody targeting the CD6 immune checkpoint receptor, in development for severe autoimmune and inflammatory disorders such as acute graft-versus-host disease, asthma, and lupus nephritis.
EQ101: A product candidate in development for the treatment of cutaneous T cell lymphoma and alopecia areata.
EQ102: A product candidate in development to treat various gastrointestinal diseases.

AI Analysis | Feedback

Equillium, Inc. (EQ) is a clinical-stage biotechnology company focused on developing product candidates for severe autoimmune and inflammatory disorders. Based on the provided background, the company's lead product candidate, itolizumab (EQ001), is in Phase III and Phase Ib clinical trials, and other candidates (EQ101 and EQ102) are also under development.

As a clinical-stage company, Equillium does not currently have major commercial customers that purchase its products, as its product candidates have not yet received regulatory approval for commercial sale. Its primary activities involve research, development, and conducting clinical trials to advance its drug candidates.

Therefore, Equillium does not sell products primarily to other companies or individuals in a commercial capacity at this time. Its "customers" in the future, if its products are approved, would likely include:

Pharmaceutical companies (for potential licensing, co-development, or acquisition deals)
Hospitals and clinics (as end-users of approved therapeutic drugs)
Patients (who would receive the treatments via healthcare providers)

However, these are future prospects upon successful approval and commercialization, not current major customers of the clinical-stage company.

AI Analysis | Feedback

Biocon Limited (BSE: 532480, NSE: BIOCON)

AI Analysis | Feedback

Bruce Steel, Chief Executive Officer

Bruce Steel is a co-founder, Director, and Chief Executive Officer of Equillium. He assumed the role of CEO effective January 1, 2020. Prior to co-founding Equillium, Mr. Steel founded and served as Managing Director of BioMed Ventures, the strategic investment arm of BioMed Realty, where he directed investments in over 30 biotechnology companies, including Auspex Pharmaceuticals and Receptos, both of which were acquired. He was also the co-founder and CEO of Rincon Pharmaceuticals, which was acquired in 2008. Additionally, he served as Chief Business Officer at Anaphore and Head of Corporate Development at Ambit Biosciences, which was acquired by Daiichi Sankyo in 2014.

Jason A. Keyes, Chief Financial Officer

Jason A. Keyes is the Chief Financial Officer of Equillium. He has nearly 25 years of experience in the biotechnology industry. Prior to joining Equillium, Mr. Keyes served as Executive Vice President and Chief Financial Officer of Orexigen Therapeutics, Inc., where he was responsible for finance, accounting, and investor relations, and provided business development leadership. Before Orexigen, he worked at Amylin Pharmaceuticals, Inc. for over five years, most recently as Senior Director of Finance, until the company was acquired by Bristol-Myers Squibb. He also held leadership positions in finance and corporate strategy at Amgen, Inc. and Baxter Healthcare Corporation. Mr. Keyes helped lead Equillium's IPO in October 2018.

Stephen Connelly, Ph.D., President and Chief Scientific Officer

Stephen Connelly is a co-founder, Director, and currently serves as President and Chief Scientific Officer of Equillium, having been promoted to President in October 2025. Prior to co-founding Equillium, he was an investment Principal at BioMed Ventures, a life sciences venture capital group, where he helped manage a venture portfolio of therapeutic, device, and diagnostic companies. He also served as Director of Business Development and Therapeutic Alliances at aTyr, assisting in raising over $150 million through private and public financings. Earlier in his career, he was a Senior Scientist at The Scripps Research Institute, working on multiple drug discovery projects.

Christine Zedelmayer, Chief Operating Officer

Christine Zedelmayer is the Chief Operating Officer of Equillium. She was promoted to Senior Vice President and Chief Operating Officer effective January 1, 2020. Prior to this, she served as Vice President of Operations at Equillium since February 2018.

Krishna Polu, M.D., Former Chief Medical Officer and Executive Vice President, Research & Development (Current: Executive in Residence at Bioqube Ventures and CEO at Commit Biologics)

Krishna Polu previously served as Chief Medical Officer and Executive Vice President, Research & Development at Equillium. Before joining Equillium, he was Chief Medical Officer at Raptor Pharmaceuticals until its acquisition by Horizon Pharmaceuticals in 2016 for $800 million. Dr. Polu also held the position of Chief Medical Officer at CytomX Therapeutics and was instrumental in securing FDA approval of peginesatide for anemia in dialysis patients at Affymax. He was an entrepreneur-in-residence at Frazier Healthcare (a venture capital firm), where he founded Expedition Therapeutics, served as interim CEO of Scout Bio, and co-founded Lassen Therapeutics. He is currently an Operating Partner with Catalys Pacific, a venture capital firm, and has been involved in co-creating several successful cardiorenal companies, including Mineralys.

AI Analysis | Feedback

Key Risks for Equillium (EQ)

Clinical Trial and Regulatory Approval Risk: Equillium's success is highly dependent on the successful completion of clinical trials for its product candidates, especially itolizumab (EQ001) which is in Phase III trials, and subsequently obtaining regulatory approvals. Failure at any stage of these trials or inability to secure regulatory approval would severely impact the company's ability to commercialize its products.
Dependence on Lead Product Candidate (Itolizumab): The company's pipeline is heavily concentrated on itolizumab (EQ001) as its lead product candidate, which is in the most advanced stages of development. The future prospects and financial performance of Equillium are significantly tied to the successful development, approval, and commercialization of itolizumab.
Competition in Immuno-inflammatory Disorders: Equillium operates in the highly competitive therapeutic area of severe autoimmune and inflammatory disorders. The company's product candidates, if approved, will face competition from existing treatments and other new therapies being developed by larger and more established pharmaceutical and biotechnology companies.

AI Analysis | Feedback

null

AI Analysis | Feedback

Equillium Inc. (EQ) is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune and inflammatory disorders. The addressable markets for its main product candidates are substantial, spanning several therapeutic areas globally and within major markets. Here's an overview of the addressable markets for Equillium's key products: * Itolizumab (EQ001)

Acute Graft-Versus-Host Disease (aGVHD): The global acute graft-versus-host disease market was valued at approximately USD 2.53 billion in 2023 and is projected to reach USD 5.45 billion by 2033. Another estimate places the global market at USD 4.07 billion in 2025, growing to USD 5.46 billion by 2032. In 2025, the global graft versus host disease treatment market size, including both acute and chronic forms, was approximately USD 3.08 billion, with acute GVHD accounting for around 58% of this market.
Asthma: The global asthma treatment market size was valued at USD 28.96 billion in 2025 and is predicted to increase to approximately USD 35.93 billion by 2034. Another source estimates the global market at USD 29.4 billion in 2025, projected to reach USD 47.2 billion by 2035. The asthma market size across the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) was approximately USD 27 billion in 2024. The U.S. asthma treatment market alone was approximately USD 21.5 billion in 2024.
Lupus Nephritis: The global lupus nephritis market size was estimated at USD 2.31 billion in 2024 and is expected to reach approximately USD 4.18 billion by 2031. The market across the 7MM (USA, France, Germany, Italy, Spain, UK, and Japan) was valued at approximately USD 1.96 billion in 2025. Another report valued the global market at USD 1.24 billion in 2023, projected to reach USD 2.17 billion by 2032. The systemic lupus erythematosus (SLE) and lupus nephritis (LN) market across the 7MM is forecast to grow from USD 2.4 billion in 2024 to USD 5.9 billion in 2034.

* EQ101

Cutaneous T-cell Lymphoma (CTCL): The global cutaneous T-cell lymphoma market size is expected to grow from USD 3.42 billion in 2024 to USD 5.65 billion by 2035. The global market was also estimated at USD 1.3 billion in 2024, projected to reach USD 2.5 billion by 2030. The market size for CTCL in the 7MM was USD 995 million in 2024, with the United States accounting for approximately 70% of this market.
Alopecia Areata: The global alopecia areata market size was estimated at USD 3.32 billion in 2024 and is expected to be worth USD 6.92 billion by 2034. Other estimates show the market growing from USD 3.58 billion in 2024 to USD 5.24 billion in 2029. The broader global alopecia market, which includes alopecia areata, was estimated at USD 9.48 billion in 2024 and is projected to reach USD 16.02 billion by 2030, with alopecia areata holding the largest market share of 34.61% in 2024.

* EQ102

Various Gastrointestinal Diseases (Inflammatory Bowel Disease - IBD): The global inflammatory bowel disease treatment market was valued at USD 26.55 billion in 2023 and rose to USD 29.57 billion in 2024. It is expected to grow from USD 28.1 billion in 2025 to USD 47.3 billion in 2034. In the United States, the IBD treatment market was estimated at USD 13.12 billion in 2024. The global market is also projected to reach USD 36.4 billion by 2032.

AI Analysis | Feedback

Expected Drivers of Future Revenue Growth for Equillium (EQ) Over the Next 2-3 Years

Equillium, Inc. (EQ), a clinical-stage biotechnology company, is expected to drive future revenue growth over the next two to three years primarily through strategic partnerships and milestone payments as its pipeline candidates advance through clinical development. Given the company's current stage and the recent termination of a significant development funding agreement, direct product sales are largely anticipated beyond this immediate timeframe.

The key drivers include:

*   New Partnerships and Licensing Agreements for Itolizumab (EQ001): Despite the U.S. FDA denying Breakthrough Therapy designation and Accelerated Approval for itolizumab in first-line acute graft-versus-host disease (aGVHD), Equillium plans to "evaluate partnering options" for this asset. Itolizumab has demonstrated positive longer-term clinical outcomes data in aGVHD and holds Orphan Drug and Fast Track designations, making it a potentially attractive candidate for new licensing or collaboration agreements that could generate upfront payments and milestone revenues.
*   Advancement of EQ504 in Ulcerative Colitis: Equillium is prioritizing the development of EQ504, a novel aryl hydrocarbon receptor (AhR) modulator for ulcerative colitis, with a Phase 1 clinical study anticipated to begin in mid-2026. Successful progression through early clinical trials and the generation of promising data could significantly increase the asset's value, potentially attracting future partnership interest or non-dilutive funding within the 2-3 year horizon. Recent financing efforts have been directed towards accelerating EQ504's development, indicating its strategic importance.
*   Progression and Potential Partnerships for EQ101 in Alopecia Areata: Following positive topline data from a Phase 2 proof-of-concept study announced in June 2024, Equillium is continuing to develop EQ101, a multi-cytokine inhibitor for alopecia areata. Further clinical development, including efforts to optimize its dose and delivery, could lead to partnership opportunities within the next 2-3 years, potentially generating revenue through licensing fees or milestone payments from collaborators.
*   Strategic Transactions involving the Multi-Cytokine Platform and EQ302: Equillium's proprietary multi-cytokine platform is considered a source of long-term value, with EQ302 (an orally delivered multi-cytokine inhibitor targeting celiac disease and other gastrointestinal/skin diseases) "positioned for partnering." Any strategic transactions or collaborations involving this platform or specific assets like EQ302 could provide important revenue streams, such as upfront payments or research funding, within the specified timeframe.


AI Analysis | Feedback
 Share Repurchases

Equillium authorized a $7.5 million share repurchase program on August 2, 2023, valid through the end of 2024.
As of December 31, 2024, approximately $0.3 million of shares were repurchased under the program, which subsequently expired with no plans for renewal.

 Share Issuance

On March 13, 2026, Equillium announced a private placement expected to raise approximately $35 million in gross proceeds through the issuance of about 18.9 million shares of common stock, including pre-funded warrants.
On August 11, 2025, the company announced a private placement for up to $50 million in gross proceeds, with an initial upfront financing of approximately $30 million in exchange for about 52.6 million shares (or pre-funded warrants).
In May 2025, stockholders approved an increase of 1,781,000 shares authorized for issuance under the 2018 Equity Incentive Plan.

 Inbound Investments

In March 2026, Equillium secured approximately $35 million in gross proceeds from RA Capital Management through a private placement to fund the development of EQ504.
In August 2025, the company entered into a private placement with healthcare investors, including ADAR1 Capital Management and Janus Henderson Investors, for up to $50 million in gross proceeds, with an initial $30 million tranche received to support EQ504 development.
In 2023, Ono Pharmaceutical paid Equillium approximately $37.2 million (JPY 5.0 billion) upon exercising an option for itolizumab, and funded itolizumab's research and development from July 2022 through the option period.

 Outbound Investments

In October 2024, Equillium acquired Ariagen, Inc. to obtain a preclinical stage therapeutic drug product, with potential future payments of up to $55.0 million tied to regulatory approvals.

 Capital Expenditures

Equillium reported adjusted capital expenditures of USD -2.0 thousand in 2025.
The company does not own or operate manufacturing facilities for its product candidates and has no immediate plans to develop them.
Capital allocation is primarily focused on the research and development of its product candidates, such as itolizumab (EQ001) and EQ504.



	
		
			
				
					
					 Interactive Breakdown
null

null
				
			
		
	

	
		
			
				
				 Better Bets vs. Equillium (EQ)
				
					By Industry
					By Sector
					All Other Sectors
					Sector Best Bets
				
				
										null
					null
					null
					null

				
			
		
	

	
		
			
				
				 Peer Outperformance in Biotechnology
				
			
				EQ has outperformed 61% of its 361 Biotechnology peers over 5Y. Biotechnology ranks 9th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
			
		
				
		
			Share of Biotechnology constituents that EQ has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
			
			
				1Y
				53%
				of 455 industry peers · 15.7% return
			
		
			
				3Y
				84%
				of 402 industry peers · 171.2% return
			
		
			
				5Y
				61%
				of 361 industry peers · -60.9% return
			
		
		
	
				null
				
			
				Median price return by industry across the Health Care sector, ranked by 5Y. Biotechnology is EQ's own industry. Use this to see which corners of the sector have carried the returns.
				
				
					
						Industry
						Names
						1Y med 3Y med 5Y med
						Top 3 by 5Y
					
					
				
					Health Care Distributors
					7
					14.0% 90.5% 127.8%
					CAH 413% · MCK 353% · COR 181%
				
			
				
					Managed Health Care
					8
					32.5% -2.2% 4.0%
					OSCR 99% · HQY 47% · ELV 16%
				
			
				
					Health Care Services
					20
					19.7% 52.7% -0.4%
					HIMS 222% · RDNT 141% · DGX 68%
				
			
				
					Health Care Facilities
					24
					-1.0% 3.1% -19.2%
					THC 254% · NHC 248% · ENSG 112%
				
			
				
					Health Care Equipment
					50
					-4.5% -5.4% -23.9%
					POCI 10775% · UFPT 332% · GKOS 198%
				
			
				
					Pharmaceuticals
					63
					-1.5% 3.5% -34.0%
					LQDA 2424% · INDV 1137% · ETON 1020%
				
			
				
					Health Care Supplies
					12
					27.9% -12.9% -35.1%
					LNTH 286% · HAE 60% · MMSI 25%
				
			
				
					Life Sciences Tools & Services
					109
					1.6% -28.3% -72.1%
					SNWV 1688% · MEDP 205% · AXGN 174%
				
			
				
					Biotechnology ←
					362
					4.7% -23.3% -78.0%
					BRTX 73900% · DNTH 1594% · CELZ 1486%
				
			
				
					Health Care Technology
					19
					-24.6% -53.2% -79.3%
					SPOK 72% · HSTM 0% · VEEV -11%
				
			
				
				
				
					Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.
				
			
		
			
		
	

	
		
			
				
				 Latest Trefis Analyses
				 Title Date
0 DASHBOARDS  
1 Equillium Earnings Notes 12/16/2025
2 Would You Still Hold Equillium Stock If It Fell Another 30%? 10/17/2025
 Title
0 ARTICLES
			
		
	

	
		
			
				
				 Trade Ideas
Select ideas related to EQ.null
			
		
	

	
		
			
				
				 Recent Active Movers
				
					1D
					1W
					1M
				
				
										Top Gainers
Ticker Company Mkt Cap (B) 1D Rtn YTD Rtn
NX Quanex Building Products 1.0 22.2% 50.5%
TYRA Tyra Biosciences 1.9 15.2% 9.0%
AEHR Aehr Test Systems 2.8 13.1% 327.2%
SNDK SanDisk 255.8 11.9% 633.0%
GOLD Gold.com 1.3 11.2% 36.6%
PSIX Power Solutions International 0.9 11.2% -29.1%
EOSE Eos Energy Enterprises 1.3 10.9% -66.1%
COHU Cohu 2.4 10.3% 118.0%
CBRS Cerebras Systems 31.7 10.3% -32.5%
ALAB Astera Labs 53.5 9.8% 86.6%
Top Losers
Ticker Company Mkt Cap (B) 1D Rtn YTD Rtn
GWRE Guidewire Software 13.7 -19.9% -19.2%
LULU Lululemon Athletica 11.6 -17.4% -51.6%
FICO Fair Isaac 21.1 -16.7% -44.9%
PATH UiPath 8.0 -16.6% -7.3%
OXM Oxford Industries 0.5 -15.7% -5.2%
ABTC American Bitcoin 0.6 -14.5% -68.7%
ASAN Asana 2.1 -12.7% -35.7%
NXTT Next Technology 0.8 -11.3% -12.8%
BALY Ballys 0.6 -10.7% -44.7%
TRON Tron 0.7 -9.8% 19.4%
					Top Gainers
Ticker Company Mkt Cap (B) 1W Rtn YTD Rtn
SMMT Summit Therapeutics 13.7 28.2% 0.7%
TARS Tarsus Pharmaceuticals 3.9 26.5% 10.9%
CNH CNH Industrial 17.8 23.3% 57.7%
FRVO Fervo Energy 2.9 23.0% -50.3%
BE Bloom Energy 72.6 20.0% 191.0%
EOSE Eos Energy Enterprises 1.3 19.0% -66.1%
NX Quanex Building Products 1.0 18.1% 50.5%
ODTX Odyssey Therapeutics 0.9 18.1% 75.2%
SECZ Securitize 1.1 18.0% -39.7%
HUT Hut 8 11.1 17.8% 103.6%
Top Losers
Ticker Company Mkt Cap (B) 1W Rtn YTD Rtn
ADBT Advasa 0.2 -93.3% -94.7%
ALMS Alumis 1.4 -50.4% 13.7%
RARE Ultragenyx Pharmaceutical 1.6 -40.3% -33.5%
TRON Tron 0.7 -28.8% 19.4%
CXM Sprinklr 1.4 -27.6% -24.0%
CRDO Credo Technology 31.5 -26.7% 18.5%
ENOV Enovis 1.1 -25.5% -30.3%
GWRE Guidewire Software 13.7 -21.1% -19.2%
OXM Oxford Industries 0.5 -19.4% -5.2%
FICO Fair Isaac 21.1 -19.2% -44.9%
					Top Gainers
Ticker Company Mkt Cap (B) 1M Rtn YTD Rtn
NXTT Next Technology 0.8 532.2% -12.8%
MRNA Moderna 57.9 170.2% 393.6%
CAPR Capricor Therapeutics 0.5 124.9% -67.4%
QMCO Quantum 0.5 111.7% 283.4%
OABI OmniAb 0.6 93.3% 134.1%
SENS Senseonics 0.6 87.0% 74.5%
PURR Hyperliquid Strategies 1.5 82.6% 242.1%
HTFL HeartFlow 4.2 79.9% 67.8%
STDN Standard Nuclear 2.4 79.3% 19.5%
ABCL AbCellera Biologics 3.5 75.0% 234.2%
Top Losers
Ticker Company Mkt Cap (B) 1M Rtn YTD Rtn
ALMS Alumis 1.4 -60.1% 13.7%
IESC IES 12.9 -47.4% -17.1%
LASR nLight 2.3 -46.9% 6.8%
CDNL Cardinal Infrastructure 0.6 -41.8% 50.7%
RARE Ultragenyx Pharmaceutical 1.6 -40.7% -33.5%
AADX Applied Aerospace & Defense 1.9 -39.2% -32.0%
AEVA Aeva Technologies 1.0 -37.9% 18.1%
FTK Flotek Industries 0.9 -35.4% 36.6%
LINC Lincoln Educational Services 0.8 -34.8% 6.2%
RXT Rackspace Technology 0.8 -33.8% 228.6%

				
			
		
	

	
		 More From Trefis
		
			
				Research & Analysis
				
					Latest Ideas
					Dip Buying Opportunities
					Earnings Reaction Data
				
			
		
		
			
				Invest in Strategies
				
					Invest in Trefis Strategies
					Advisor Strategies & Resources
				
			
		
		
			
				Wealth Management
				
					Help Me Invest
					Rules-Based Wealth Management
				
			
		
	

	
		
			
				 Peer Comparisons
Peers to compare with: 
				
				Financials
 EQ VRTX APMD ATTO BLSM BRVE Median
Name Equillium Vertex P. Apnimed  Attovia . BlossomH. Bravehea.  
Mkt Price 2.21 546.12 27.45 25.55 22.01 26.74 26.14
Mkt Cap 0.2 138.6 - - - - 69.4
Rev LTM 0 12,587 - 0 - - 0
Op Inc LTM -19 4,777 - -74 - - -19
FCF LTM -20 3,796 - -64 - - -20
FCF 3Y Avg -19 1,957 - - - - 969
CFO LTM -20 4,293 - -62 - - -20
CFO 3Y Avg -19 2,398 - - - - 1,190
				Growth & Margins
 EQ VRTX APMD ATTO BLSM BRVE Median
Name Equillium Vertex P. Apnimed  Attovia . BlossomH. Bravehea.  
Rev Chg LTM -100.0% 10.2% - - - - -44.9%
Rev Chg 3Y Avg -45.0% 9.8% - - - - -17.6%
Rev Chg Q - 12.5% - - - - 12.5%
QoQ Delta Rev Chg LTM - 3.0% - - - - 3.0%
Op Inc Chg LTM 5.7% 2,497.9% - - - - 1,251.8%
Op Inc Chg 3Y Avg -18.8% 792.2% - - - - 386.7%
Op Mgn LTM - 37.9% - -16,551.6% - - -8,256.8%
Op Mgn 3Y Avg - 23.9% - - - - 23.9%
QoQ Delta Op Mgn LTM - -0.2% - - - - -0.2%
CFO/Rev LTM - 34.1% - -13,695.3% - - -6,830.6%
CFO/Rev 3Y Avg - 19.6% - - - - 19.6%
FCF/Rev LTM - 30.2% - -14,194.7% - - -7,082.3%
FCF/Rev 3Y Avg - 15.7% - - - - 15.7%
				Valuation
 EQ VRTX APMD ATTO BLSM BRVE Median
Name Equillium Vertex P. Apnimed  Attovia . BlossomH. Bravehea.  
Mkt Cap 0.2 138.6 - - - - 69.4
P/S - 11.0 - - - - 11.0
P/Op Inc -12.8 29.0 - - - - 8.1
P/EBIT -12.8 27.5 - - - - 7.3
P/E -13.7 31.5 - - - - 8.9
P/CFO -12.4 32.3 - - - - 10.0
Total Yield -7.3% 3.2% - - - - -2.1%
Dividend Yield 0.0% 0.0% - - - - 0.0%
FCF Yield 3Y Avg -88.9% 1.6% - - - - -43.6%
D/E 0.0 0.0 - - - - 0.0
Net D/E -0.2 -0.0 - - - - -0.1
				Returns
 EQ VRTX APMD ATTO BLSM BRVE Median
Name Equillium Vertex P. Apnimed  Attovia . BlossomH. Bravehea.  
1M Rtn 4.7% 10.1% 1.7% 26.7% 37.6% -10.9% 7.4%
3M Rtn -24.8% 22.2% 9.8% 16.7% 37.6% -10.3% 13.2%
6M Rtn 24.9% 19.6% 9.8% 16.7% 37.6% -10.3% 18.1%
12M Rtn 15.7% 37.9% 9.8% 16.7% 37.6% -10.3% 16.2%
3Y Rtn 171.2% 58.8% 9.8% 16.7% 37.6% -10.3% 27.1%
1M Excs Rtn 4.1% 12.7% -1.7% 25.3% 37.5% -10.4% 8.4%
3M Excs Rtn -29.4% 17.7% 5.3% 12.1% 33.0% -14.8% 8.7%
6M Excs Rtn 10.3% 5.1% -4.7% 2.1% 23.0% -24.8% 3.6%
12M Excs Rtn 7.6% 18.9% -8.9% -2.0% 18.9% -29.0% 2.8%
3Y Excs Rtn 104.6% -15.3% -61.2% -54.3% -33.4% -81.2% -43.8%
				Comparison Analyses
null
			
		
	

	
		
			
				
				 FDIC Bank Data
				
					Capital & Deposits
					Assets
					Loans
				
				
										Bank Capital
nullBank Deposits
null
					Bank Assets
null
					Bank Loans
null

				
			
		
	

	
		
			
				
				 FDA Approved Drugs Data
				Expand for Morenull
				Collapse to Previewnull
			
		
	

	
		
			
				
				 Clinical Pipeline
				null
			
		
	

	
		
			
				
				 Financials
				
					Annual
					Quarterly
				
									$ Mil | FY: 12/31 LTM 2025 2024 2023 2022 2021 2020
Period End 6/30/2026 12/31/2025 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Filing Date 8/13/2026 3/25/2026 3/27/2025 3/25/2024 3/23/2023 3/23/2022 3/24/2021

Key Financials              
Total Revenue 0 0 41 36 16 0 0
Gross Profit - - - - - - -
EBITDA -19 -24 -8 -12 -61 -38 -29
Operating Income -19 -24 -8 -15 -39 -38 -30
Net Income -18 -22 -8 -13 -62 -39 -30
EPS -0.20 -0.39 -0.23 -0.38 -1.85 -1.36 -1.46

Growth Rates              
Total Revenue Growth -100.0% -100.0% 13.9% 129.0% ∞% - -
EBITDA Growth 5.6% -189.2% 33.0% 80.2% -61.6% -32.2% -13.3%
Operating Income Growth 5.7% -185.8% 43.1% 62.8% -3.3% -27.9% -10.6%
Net Income Growth 10.8% -177.6% 39.5% 78.6% -59.9% -31.0% -16.5%

Margins              
Gross Margin - - - - - - -
EBITDA Margin - - -19.8% -33.6% -388.7% - -
Operating Income Margin - - -20.1% -40.2% -247.6% - -
Net Income Margin - - -19.6% -37.0% -396.1% - -

Cash & Debt              
Total Cash 57 30 23 41 71 81 82
Total Debt 1 1 0 1 10 12 10
Net Debt / (Cash) -57 -30 -22 -40 -61 -69 -72

Cash Flows & CapEx              
Net Cash from Operations -20 -23 -19 -22 -9 -32 -25
Total CapEx -0 -0 -0 -0 -0 -0 -0
Free Cash from Operations -20 -23 -19 -22 -9 -32 -25

Returns to Shareholders              
Dividends 0 -0 -0 -0 -0 -0 -0
Share Repurchases -0 -0 -0 0 -0 -0 -0
					$ Mil | FY: 12/31 2026Q2 2026Q1 2025Q4 2025Q3 2025Q2 2025Q1 2024Q4 2024Q3 2024Q2 2024Q1 2023Q4 2023Q3
Period End 6/30/2026 3/31/2026 12/31/2025 9/30/2025 6/30/2025 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023
Filing Date 8/13/2026 5/13/2026 3/25/2026 11/13/2025 8/14/2025 5/14/2025 3/27/2025 11/13/2024 8/8/2024 5/9/2024 3/25/2024 11/8/2023

Key Financials Quarterly                        
Total Revenue 0 0 0 0 0 0 4 12 14 11 9 9
Ebitda -5 -6 -4 -5 -6 -9 -5 -1 -0 -3 -2 -3
Operating Income -5 -6 -4 -5 -6 -9 -5 -1 -0 -3 -3 -4
Net Income -5 -5 -4 -4 -6 -9 -6 -0 0 -3 -2 -4
EPS -0.04 -0.06 -0.04 -0.06 -0.16 -0.24 -0.16 0.00 0.01 -0.08 -0.07 -0.11

Key Financials TTM                        
Total Revenue TTM 0 0 0 4 17 30 41 46 43 38 36 43
Ebitda TTM -19 -20 -24 -24 -20 -14 -8 -6 -8 -11 -12 -7
Operating Income TTM -19 -20 -24 -24 -20 -14 -8 -7 -10 -13 -15 -9
Net Income TTM -18 -19 -22 -24 -20 -14 -8 -5 -8 -12 -13 -8

Growth Rates Quarterly                        
Total Revenue Growth - - -100.0% -100.0% -100.0% -100.0% -52.3% 37.1% 51.8% 20.4% -41.6% -
EBITDA Growth 17.2% 36.8% 15.5% -606.1% -9432.3% -220.3% -103.4% 79.8% 97.9% 23.7% -174.5% 76.2%
Operating Income Growth 17.2% 36.8% 15.7% -573.8% -6128.0% -217.8% -46.8% 81.3% 97.2% 32.1% -256.7% 72.6%
Net Income Growth 18.2% 38.6% 34.8% -60328.6% -1326.3% -216.5% -147.4% 99.8% 114.0% 30.6% -184.5% 72.8%

Margins Quarterly                        
EBITDA Margin - - - - - - -106.2% -5.3% -0.5% -25.8% -24.9% -35.9%
Operating Income Margin - - - - - - -107.0% -5.6% -0.7% -26.1% -34.7% -40.8%
Net Income Margin - - - - - - -131.9% -0.1% 3.4% -25.6% -25.4% -41.8%

Cash & Debt                        
Total Cash 57 61 30 33 11 15 23 26 33 32 41 46
Total Debt 1 1 1 1 0 0 0 0 1 1 1 1
Net Debt / (Cash) -57 -61 -30 -32 -11 -14 -22 -25 -33 -32 -40 -45

Cash Flows Quarterly                        
FCF from Operations -4 -4 -3 -8 -3 -8 -3 -8 1 -9 -6 -2

Cash Flows TTM                        
FCF from Operations TTM -20 -19 -23 -23 -22 -18 -19 -21 -16 -23 -22 12

Returns to Shareholders Quarterly                        
Dividends 0 0 0 0 0 0 0 0 0 0 0 0
Share Repurchases -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0

Return on Invested Capital (ROIC) Quarterly                        
ROIC -9.1% -10.2% -7.4% -8.7% -12.3% -17.8% -9.9% -1.5% -0.2% -6.3% -7.6% -8.9%

Return on Invested Capital (ROIC) TTM                        
ROIC TTM -8.6% -9.2% -11.0% -11.6% -10.1% -7.2% -4.3% -3.6% -5.5% -7.4% -8.6% -5.7%

			
		
	

	
		
			
				
				 Segment Financials
Revenue by Segment
$ Mil 2025 2024 2023 2022
Developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to 0 41 36  
Single Segment       16
Total 0 41 36 16


Assets by Segment
$ Mil 2025 2024 2021 2020 2019
Developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to 32 26      
Single Segment     85 85 56
Total 32 26 85 85 56



			
		
	

	
		
			
				
				 Price Behavior
				
					Behavior Stats
					Betas Matrix
					Behavior vs Other Asset Classes
				
				
										Price Behavior
Market Price $2.21  
Market Cap ($ Bil) 0.2  
First Trading Date 10/12/2018  
Distance from 52W High -30.9%  
    50 Days 200 Days
DMA Price $2.46 $1.98
DMA Trend up down
Distance from DMA -10.0% 11.6%
  3M 1YR
Volatility 74.0% 105.3%
Downside Capture 41.91 148.44
Upside Capture -96.41 134.24
Correlation (SPY) 9.4% 16.1%
					
EQ Betas & Captures as of 8/31/2026


  1M 2M 3M 6M 1Y 3Y
Beta 0.54 -0.13 0.34 1.46 1.31 0.85
Up Beta -0.42 1.61 2.03 2.37 1.00 0.48
Down Beta 7.67 2.34 1.20 1.23 1.45 1.27
Up Capture 54% -194% -90% 139% 162% 123%
Bmk +ve Days 10 21 32 68 138 427
Stock +ve Days 8 14 25 59 112 349
Down Capture 10% -18% 4% 107% 120% 96%
Bmk -ve Days 11 21 32 59 113 324
Stock -ve Days 12 27 37 65 130 380


[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
					
					1Y
					5Y
					10Y
				
					Based On 1-Year Data
 Annualized
Return Annualized
Volatility Sharpe
Ratio Correlation
with EQ
EQ 26.4% 105.2% 0.69 -
Sector ETF (XLV) 26.5% 16.0% 1.28 4.2%
Equity (SPY) 19.7% 12.8% 1.13 16.1%
Gold (GLD) 24.6% 29.2% 0.75 5.7%
Commodities (DBC) 43.8% 20.3% 1.67 -2.9%
Real Estate (VNQ) 9.1% 13.6% 0.39 -5.9%
Bitcoin (BTCUSD) -28.1% 43.8% -0.63 3.1%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
					Based On 5-Year Data
 Annualized
Return Annualized
Volatility Sharpe
Ratio Correlation
with EQ
EQ -18.8% 114.5% 0.31 -
Sector ETF (XLV) 6.6% 15.1% 0.25 7.7%
Equity (SPY) 12.8% 17.2% 0.57 10.7%
Gold (GLD) 19.1% 18.8% 0.82 1.5%
Commodities (DBC) 10.7% 19.5% 0.43 0.7%
Real Estate (VNQ) 1.7% 18.9% -0.01 7.6%
Bitcoin (BTCUSD) 10.2% 52.6% 0.38 7.2%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
					Based On 10-Year Data
 Annualized
Return Annualized
Volatility Sharpe
Ratio Correlation
with EQ
EQ -16.9% 284.6% 0.36 -
Sector ETF (XLV) 10.8% 16.7% 0.53 5.0%
Equity (SPY) 15.3% 17.9% 0.72 3.4%
Gold (GLD) 12.4% 16.3% 0.62 1.0%
Commodities (DBC) 7.9% 18.1% 0.35 -0.3%
Real Estate (VNQ) 4.8% 20.7% 0.19 2.1%
Bitcoin (BTCUSD) 63.7% 66.2% 1.03 2.2%

Smart multi-asset allocation framework can stack odds in your favor. Learn How


				
			
		
		
			
				
				 Short Interest
Short Interest: As Of Date 8142026
Short Interest: Shares Quantity 5.5 Mil
Short Interest: % Change Since 7312026 2.2%
Average Daily Volume 0.6 Mil
Days-to-Cover Short Interest 10
Basic Shares Quantity 111.8 Mil
Short % of Basic Shares 4.9%
			
		
	

	
		
			
				 Returns Analyses
 Title
0 Would You Still Hold Equillium Stock If It Fell Another 30%?
			
		
	

	
		
			
				
				
				    Earnings Returns History
				    Updated 8/24/2026
				

				Expand for More  Forward Returns
Earnings Date 1D Returns 5D Returns 21D Returns
8/13/2026 17.4% 12.9%  
5/13/2026 12.1% -10.8% 21.6%
3/25/2026 0.0% -1.0% 4.9%
11/13/2025 23.8% 20.2% 44.0%
8/4/2025 -20.7% -30.3% 142.3%
4/24/2025 -2.1% -12.5% -17.5%
11/13/2024 -12.3% -8.0% -9.7%
8/8/2024 -1.5% 13.9% 25.8%
... 
SUMMARY STATS      
# Positive 12 12 10
# Negative 11 11 12
Median Positive 4.6% 12.1% 25.2%
Median Negative -4.7% -12.5% -14.7%
Max Positive 44.8% 28.4% 142.3%
Max Negative -20.7% -32.3% -60.7%
				Collapse to Preview  Forward Returns
Earnings Date 1D Returns 5D Returns 21D Returns
8/13/2026 17.4% 12.9%  
5/13/2026 12.1% -10.8% 21.6%
3/25/2026 0.0% -1.0% 4.9%
11/13/2025 23.8% 20.2% 44.0%
8/4/2025 -20.7% -30.3% 142.3%
4/24/2025 -2.1% -12.5% -17.5%
11/13/2024 -12.3% -8.0% -9.7%
8/8/2024 -1.5% 13.9% 25.8%
5/9/2024 -15.0% -14.4% -60.7%
11/8/2023 -4.7% 0.0% 36.0%
8/9/2023 3.9% 6.2% 6.6%
5/11/2023 2.1% 2.6% 24.5%
3/23/2023 11.5% 11.3% -5.7%
11/14/2022 5.3% 2.9% -29.1%
8/15/2022 -1.2% -3.9% -27.4%
5/12/2022 0.9% 12.9% -9.8%
3/23/2022 -0.3% -3.9% -10.6%
11/10/2021 -8.8% -13.0% -23.0%
8/10/2021 0.3% -14.6% -4.6%
5/13/2021 3.2% 26.3% 14.1%
3/24/2021 -0.4% 3.8% -11.9%
11/10/2020 44.8% 28.4% 36.8%
8/12/2020 -11.3% -32.3% -49.4%
SUMMARY STATS      
# Positive 12 12 10
# Negative 11 11 12
Median Positive 4.6% 12.1% 25.2%
Median Negative -4.7% -12.5% -14.7%
Max Positive 44.8% 28.4% 142.3%
Max Negative -20.7% -32.3% -60.7%
			
		
		
			
				
				 SEC Filings
				Expand for MoreReport Date Filing Date Filing
06/30/2026 08/13/2026 10-Q
03/31/2026 05/13/2026 10-Q
12/31/2025 03/25/2026 10-K
09/30/2025 11/13/2025 10-Q
06/30/2025 08/14/2025 10-Q
03/31/2025 05/14/2025 10-Q
12/31/2024 03/27/2025 10-K
09/30/2024 11/13/2024 10-Q
06/30/2024 08/08/2024 10-Q
03/31/2024 05/09/2024 10-Q
12/31/2023 03/25/2024 10-K
09/30/2023 11/08/2023 10-Q
06/30/2023 08/09/2023 10-Q
03/31/2023 05/11/2023 10-Q
12/31/2022 03/23/2023 10-K
09/30/2022 11/14/2022 10-Q
				Collapse to PreviewReport Date Filing Date Filing
06/30/2026 08/13/2026 10-Q
03/31/2026 05/13/2026 10-Q
12/31/2025 03/25/2026 10-K
09/30/2025 11/13/2025 10-Q
06/30/2025 08/14/2025 10-Q
03/31/2025 05/14/2025 10-Q
12/31/2024 03/27/2025 10-K
09/30/2024 11/13/2024 10-Q
06/30/2024 08/08/2024 10-Q
03/31/2024 05/09/2024 10-Q
12/31/2023 03/25/2024 10-K
09/30/2023 11/08/2023 10-Q
06/30/2023 08/09/2023 10-Q
03/31/2023 05/11/2023 10-Q
12/31/2022 03/23/2023 10-K
09/30/2022 11/14/2022 10-Q
06/30/2022 08/15/2022 10-Q
03/31/2022 05/12/2022 10-Q
12/31/2021 03/23/2022 10-K
09/30/2021 11/10/2021 10-Q
06/30/2021 08/10/2021 10-Q
03/31/2021 05/13/2021 10-Q
12/31/2020 03/24/2021 10-K
09/30/2020 11/10/2020 10-Q
06/30/2020 08/12/2020 10-Q
03/31/2020 05/13/2020 10-Q
12/31/2019 03/26/2020 10-K
09/30/2019 11/12/2019 10-Q
			
		
	

	
		
			
				
				
				    Recent Forward Guidance
				    Updated 8/14/2026
				
				Latest: Q2 2026 Earnings Reported 8/13/2026
				Forward Guidance Guidance Change
Metric Source Low Mid High % Chg % Delta Change Prior
2029 Cash Runway Reported             
				
Prior: Q1 2026 Earnings Reported 5/13/2026
				Forward Guidance Guidance Change
Metric Source Low Mid High % Chg % Delta Change Prior
2029 Cash Runway Reported           Affirmed Guidance: 2,029 for 2029

Q4 2025 Earnings Reported 3/25/2026
Forward Guidance Guidance Change
Metric Source Low Mid High % Chg % Delta Change Prior
2029 Operating Runway Reported   2,029       Raised Guidance: 2,027 for 2027

Q3 2025 Earnings Reported 11/13/2025
Forward Guidance Guidance Change
Metric Source Low Mid High % Chg % Delta Change Prior
2027 Operational Runway Reported             
			
		
	

	
		
			
				
				
				    Insider Activity
				    Updated 6/5/2026
				
				Expand for More# Owner Title Holding Action Filing Date Price Shares Transacted
Value Value of
Held Shares Form
1 Zedelmayer, Christine Sr. Vice President and COO Direct Sell 6052026 2.93 14,584 42,737 183,402 Form
2 Connelly, Stephen President and CSO Direct Sell 6052026 2.94 30,975 91,070 2,240,430 Form
3 Connelly, Stephen President and CSO Direct Sell 6052026 3.16 200,000 632,760 2,508,893 Form
4 Tom, Penny Principal Accounting Officer Direct Sell 5292026 2.95 65,000     Form
5 Zedelmayer, Christine Sr. Vice President and COO Direct Sell 5292026 2.80 86,012 240,693 175,138 Form
				Collapse to Preview# Owner Title Holding Action Filing Date Price Shares Transacted
Value Value of
Held Shares Form
1 Zedelmayer, Christine Sr. Vice President and COO Direct Sell 6052026 2.93 14,584 42,737 183,402 Form
2 Connelly, Stephen President and CSO Direct Sell 6052026 2.94 30,975 91,070 2,240,430 Form
3 Connelly, Stephen President and CSO Direct Sell 6052026 3.16 200,000 632,760 2,508,893 Form
4 Tom, Penny Principal Accounting Officer Direct Sell 5292026 2.95 65,000     Form
5 Zedelmayer, Christine Sr. Vice President and COO Direct Sell 5292026 2.80 86,012 240,693 175,138 Form
6 Zedelmayer, Christine Sr. Vice President and COO Direct Sell 5292026 2.70 9,821 26,517 168,982 Form
7 Zedelmayer, Christine Sr. Vice President and COO Direct Sell 3162026 2.50 120,312 300,816 156,484 Form
8 Zedelmayer, Christine Sr. Vice President and COO Direct Sell 3102026 2.00 181,219 362,438 125,172 Form
9 Zedelmayer, Christine Sr. Vice President and COO Direct Sell 2232026 1.76 185,937 328,104 337,822 Form
10 Tom, Penny Principal Accounting Officer Direct Sell 1092026 1.29 6,533     Form
11 Zedelmayer, Christine Sr. Vice President and COO Direct Sell 12232025 1.50 100,000 150,000 137,166 Form
12 Zedelmayer, Christine Sr. Vice President and COO Direct Sell 12152025 1.31 11,900 15,589 119,792 Form
13 Zedelmayer, Christine Sr. Vice President and COO Direct Sell 12152025 1.34 23,804 31,897 138,481 Form
14 Zedelmayer, Christine Sr. Vice President and COO Direct Sell 11252025 0.95 8,098 7,696 120,838 Form
			
		
	
	
	
		
			
				
				
					Investor Activity (13F)
					Updated Sep 7, 2026
				
				13F holdings as of Mar 31, 2026 (Q1 2026)
				Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
				
					
					
					
					
				
				
					Active Manager Value % of Portfolio Total Positions QoQ Filing
Decheng Capital LLC $8.9 Mil 1.3% 14 Hold 13F
					Active Manager
					Active Manager
					Active Manager Value % of Portfolio Total Positions QoQ Filing
Decheng Capital LLC $8.9 Mil 1.3% 14 Hold 13F
				
			
		
	
	
	
	
	
	
		
			
				
				 EQ Trade Sentinel
				
				
					
						
					
					
						
					
					
						
					
					
						
					
				
				
				
				
				
					
						
							
								
									
										Stock Conviction									
										null
									
								
								
									
										CONVICTION RATIONALE
										null
									
								
								
									
										
											STOCK ARCHETYPE
											null
										
										null
									
								
							

							
								Looking for high-conviction positions with a better risk/reward profile? See what's currently in the 
								Trefis High Quality Portfolio.
							

							
								
									
										INVESTMENT THESIS
										null
										null
										
										
											Mechanism:
											null
										
										
										
											Supporting Evidence:
											
												
											
										
									
								
								
								
									
										PRIMARY RISK
										null
										null
										
										
											Mechanism:
											null
										
										
										
											Supporting Evidence:
											
												
											
										
									
								
							

							
								Key KPI Watchlist
								
									
										
											
												
													KPI
													Status
													Rationale
												
											
											
												
											
										
									
								
							

						
					

					
						
							
								Core Investment Debate
								
							

							
								
									
										BULL VIEW
										
									
								
								
									
										CORE TENSION
										
										
										PREVAILING SENTIMENT
										
										
									
								
								
									
										BEAR VIEW
										
									
								
							

							
								Next 6 months: Risks and Catalysts
								
									
										
											
												
													Timeline
													Event & Metric To Watch
												
											
											
												
											
										
									
								
							

							
								Key Events in Last 6 Months
								
									
										
											
												
													Date
													Event
													Stock Impact
												
											
											
												
											
										
									
								
							

							
								Risk Management
								
									
										
											 Position Sizing
											
											
											
										
										
											 Diversification Alternatives
											
												
											
										
									
								
							
						
					

					
						
							How Is The Market Pricing EQ?

							
								
									
								
							

							
								
									
								
							

							
								
									
										 What will confirm the thesis
										
									
								

								
									
										 What will damage the thesis
										
									
								

								
									
										 Noise: Real but irrelevant to thesis
										
									
								
							

							
								Repricing Catalyst
								
							

							
								What EQ Makes & Who Pays

								
									
										TTM figures based on 
									
								
								
								
									
								
							

							
								EQ Evolution: Price Return by Era
								
								
								

								
									
										
									
								
							

						
					

	
					
						
						
							
							
								
								

								
									
										① Structure
										
											0
											
										
										
									
									
										② Volume / Momentum
										
											0
											
										
										
									
									
										③ Catalyst
										
											0
											
										
										
									
								

								
									Combined Score
									
										
									
									0 / 12
								
							

							
								
									1
									Price Structure & Trend
									 · 
									▾
								
								
									
										▲
										
									

									
										
											Current
											$
											
											
										
										
											20D SMA
											$
											
											
										
										
											50D SMA
											$
											Slope: %
											
										
										
											200D SMA
											$
											Slope: %
											
										
									

									
										✕
										 —  trading days ago
									

									
										
											52W High
											$
										
										
											From 52W High
											%
										
										
											All-Time High
											$
										
										
											From ATH
											%
										
									
									
										
											52W Low
											$
										
										
											From 52W Low
											%
										
									
								
							

							
								
									2
									Momentum
									
									▾
								
								
									
										↑
										
									

									
										
											5D
											%
											
										
										
											20D
											%
											
										
										
											63D
											%
											
										
										
											126D
											%
											
										
										
											252D
											%
											
										
									
								
							

							
								
									3
									Relative Strength vs. SPY
									
									▾
								
								
									
										↑
										
									

									
										
											20D
											
											%
										
										
											63D
											
											%
										
										
											126D
											
											%
										
										
											252D
											
											%
										
									

									
										
											RS Trend
											%
										
										
											RS Character
											
										
									
								
							

							
								
									4
									Institutional Footprint & Volume
									
									▾
								
								
									
										↓
										
									
									
										◈
										
									

									
										
											Score
											
										
										
											Up/Down Vol 20D
											
										
										
											Up/Down Vol 60D
											
										
									
									
										
											OBV Slope 20D
											
										
										
											OBV Slope 60D
											
										
										
											Hi-Conv Up Days
											
											Past 60D
										
										
											Hi-Conv Down Days
											
											Past 60D
										
									
									
										
											Volume Trend
											
											20D avg vs 60D avg
										
										
									
								
							

							
								
									5
									Volatility
									
									▾
								
								
									
										≈
										
									
									
										
											HV 20D
											%
										
										
											HV 60D
											%
										
										
											HV 252D
											%
										
									
									
										
											Compression Ratio
											
										
										
											ATR 14D
											%
										
									
								
							

							
								
									6
									Key Price Levels
									Range · Vol 
									▾
								
								
									
										◈
										
									
									
										
											Nearest Resistance
											$
											% away ·  touches
										
										
											Nearest Support
											$
											% away ·  touches
										
										
											2nd Support
											$
											 touches
										
										
											Risk / Reward
											×
										
									
									
										
											Approach Volume
											
										
										
											Current Price
											$
										
									
								
							

							
								
									7
									Earnings Reaction History
									
									▾
								
								
									
										★
										
									
									
										
											
												
												
											
											
												%
												Earnings Day Return · Vol Spike ×
												
													
														5D
														%
													
													
														10D
														%
													
													
														20D
														%
													
													
														Post Vol
														×
													
												
												
												
											
										
										
											
												
												
											
											
												%
												Earnings Day Return · Vol Spike ×
												
													
														5D
														%
													
													
														10D
														%
													
													
														20D
														%
													
													
														Post Vol
														×
													
												
												
												
											
										
									
								
							

							
								
									8
									How the Verdict Is Derived
									Three Pillars
									▾
								
								
									
										
											
												Pillar
												Score
											
										
										
											
												① Structure
												0
											
											
												② Vol / Mom
												0
											
											
												③ Catalyst
												0
											
										
									
									
										ℹ
										
											Bull Pillars: 0 ·
											Bear Pillars: 0 ·
											Combined Score: 0 →
											
										
									
								
							

							
								Price Intelligence is derived from price-volume pattern analysis only. All moving averages are simple (SMA). Relative strength benchmarked against SPY.
							
						
					
					
				

				
			
		
	
	
	
		
			
				
				
			
		
	
	
		
			
				
				 Industry Resources
Health Care Resources
U.S. National Library of Medicine
ClinicalTrials.gov
Modern Healthcare
Healthcare Dive
Fierce Healthcare
Health Affairs
Health Data Management
FDA Tracker
Biotechnology Resources
Fierce Biotech
Nature Biotechnology
Genetic Engineering & Biotechnology News
Biotechnology Innovation Organization
BioWorld
BioTechniques
HBS Biotechnology Publications
			
		
		
			
				
				 External Quote Links
0 Y Finance Barrons
1 TradingView Morningstar
2 SeekingAlpha ValueLine
3 Motley Fool Robinhood
4 CNBC Etrade
5 MarketWatch Unusual Whales
6 YCharts Perplexity Finance
7 FinViz  

Prefer one of these to Trefis? Tell us why. 
			
		
	

	
		
		        Core Cache Last Updated: 9/6/2026

Pillar	Score
① Structure	0
② Vol / Mom	0
③ Catalyst	0

Industry	Names	1Y med	3Y med	5Y med	Top 3 by 5Y
Health Care Distributors	7	14.0%	90.5%	127.8%	CAH 413% · MCK 353% · COR 181%
Managed Health Care	8	32.5%	-2.2%	4.0%	OSCR 99% · HQY 47% · ELV 16%
Health Care Services	20	19.7%	52.7%	-0.4%	HIMS 222% · RDNT 141% · DGX 68%
Health Care Facilities	24	-1.0%	3.1%	-19.2%	THC 254% · NHC 248% · ENSG 112%
Health Care Equipment	50	-4.5%	-5.4%	-23.9%	POCI 10775% · UFPT 332% · GKOS 198%
Pharmaceuticals	63	-1.5%	3.5%	-34.0%	LQDA 2424% · INDV 1137% · ETON 1020%
Health Care Supplies	12	27.9%	-12.9%	-35.1%	LNTH 286% · HAE 60% · MMSI 25%
Life Sciences Tools & Services	109	1.6%	-28.3%	-72.1%	SNWV 1688% · MEDP 205% · AXGN 174%
Biotechnology ←	362	4.7%	-23.3%	-78.0%	BRTX 73900% · DNTH 1594% · CELZ 1486%
Health Care Technology	19	-24.6%	-53.2%	-79.3%	SPOK 72% · HSTM 0% · VEEV -11%

	Title	Date
0	DASHBOARDS
1	Equillium Earnings Notes	12/16/2025
2	Would You Still Hold Equillium Stock If It Fell Another 30%?	10/17/2025

	EQ	VRTX	APMD	ATTO	BLSM	BRVE	Median
Name	Equillium	Vertex P.	Apnimed	Attovia .	BlossomH.	Bravehea.
Mkt Price	2.21	546.12	27.45	25.55	22.01	26.74	26.14
Mkt Cap	0.2	138.6	-	-	-	-	69.4
Rev LTM	0	12,587	-	0	-	-	0
Op Inc LTM	-19	4,777	-	-74	-	-	-19
FCF LTM	-20	3,796	-	-64	-	-	-20
FCF 3Y Avg	-19	1,957	-	-	-	-	969
CFO LTM	-20	4,293	-	-62	-	-	-20
CFO 3Y Avg	-19	2,398	-	-	-	-	1,190

$ Mil	2025	2024	2023	2022
Developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to	0	41	36
Single Segment				16
Total	0	41	36	16

Market Price	$2.21
Market Cap ($ Bil)	0.2
First Trading Date	10/12/2018
Distance from 52W High	-30.9%
	50 Days	200 Days
DMA Price	$2.46	$1.98
DMA Trend	up	down
Distance from DMA	-10.0%	11.6%
	3M	1YR
Volatility	74.0%	105.3%
Downside Capture	41.91	148.44
Upside Capture	-96.41	134.24
Correlation (SPY)	9.4%	16.1%

	1M	2M	3M	6M	1Y	3Y
Beta	0.54	-0.13	0.34	1.46	1.31	0.85
Up Beta	-0.42	1.61	2.03	2.37	1.00	0.48
Down Beta	7.67	2.34	1.20	1.23	1.45	1.27
Up Capture	54%	-194%	-90%	139%	162%	123%
Bmk +ve Days	10	21	32	68	138	427
Stock +ve Days	8	14	25	59	112	349
Down Capture	10%	-18%	4%	107%	120%	96%
Bmk -ve Days	11	21	32	59	113	324
Stock -ve Days	12	27	37	65	130	380

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with EQ
EQ	26.4%	105.2%	0.69	-
Sector ETF (XLV)	26.5%	16.0%	1.28	4.2%
Equity (SPY)	19.7%	12.8%	1.13	16.1%
Gold (GLD)	24.6%	29.2%	0.75	5.7%
Commodities (DBC)	43.8%	20.3%	1.67	-2.9%
Real Estate (VNQ)	9.1%	13.6%	0.39	-5.9%
Bitcoin (BTCUSD)	-28.1%	43.8%	-0.63	3.1%

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with EQ
EQ	-18.8%	114.5%	0.31	-
Sector ETF (XLV)	6.6%	15.1%	0.25	7.7%
Equity (SPY)	12.8%	17.2%	0.57	10.7%
Gold (GLD)	19.1%	18.8%	0.82	1.5%
Commodities (DBC)	10.7%	19.5%	0.43	0.7%
Real Estate (VNQ)	1.7%	18.9%	-0.01	7.6%
Bitcoin (BTCUSD)	10.2%	52.6%	0.38	7.2%

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with EQ
EQ	-16.9%	284.6%	0.36	-
Sector ETF (XLV)	10.8%	16.7%	0.53	5.0%
Equity (SPY)	15.3%	17.9%	0.72	3.4%
Gold (GLD)	12.4%	16.3%	0.62	1.0%
Commodities (DBC)	7.9%	18.1%	0.35	-0.3%
Real Estate (VNQ)	4.8%	20.7%	0.19	2.1%
Bitcoin (BTCUSD)	63.7%	66.2%	1.03	2.2%

Short Interest: As Of Date	8142026
Short Interest: Shares Quantity	5.5 Mil
Short Interest: % Change Since 7312026	2.2%
Average Daily Volume	0.6 Mil
Days-to-Cover Short Interest	10
Basic Shares Quantity	111.8 Mil
Short % of Basic Shares	4.9%

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
8/13/2026	17.4%	12.9%
5/13/2026	12.1%	-10.8%	21.6%
3/25/2026	0.0%	-1.0%	4.9%
11/13/2025	23.8%	20.2%	44.0%
8/4/2025	-20.7%	-30.3%	142.3%
4/24/2025	-2.1%	-12.5%	-17.5%
11/13/2024	-12.3%	-8.0%	-9.7%
8/8/2024	-1.5%	13.9%	25.8%
...
SUMMARY STATS
# Positive	12	12	10
# Negative	11	11	12
Median Positive	4.6%	12.1%	25.2%
Median Negative	-4.7%	-12.5%	-14.7%
Max Positive	44.8%	28.4%	142.3%
Max Negative	-20.7%	-32.3%	-60.7%

Report Date	Filing Date	Filing
06/30/2026	08/13/2026	10-Q
03/31/2026	05/13/2026	10-Q
12/31/2025	03/25/2026	10-K
09/30/2025	11/13/2025	10-Q
06/30/2025	08/14/2025	10-Q
03/31/2025	05/14/2025	10-Q
12/31/2024	03/27/2025	10-K
09/30/2024	11/13/2024	10-Q
06/30/2024	08/08/2024	10-Q
03/31/2024	05/09/2024	10-Q
12/31/2023	03/25/2024	10-K
09/30/2023	11/08/2023	10-Q
06/30/2023	08/09/2023	10-Q
03/31/2023	05/11/2023	10-Q
12/31/2022	03/23/2023	10-K
09/30/2022	11/14/2022	10-Q

Forward Guidance					Guidance Change
Metric	Source	Low	Mid	High	% Chg	% Delta	Change	Prior
2029 Cash Runway	Reported

#	Owner	Title	Holding	Action	Filing Date	Price	Shares	Transacted Value	Value of Held Shares	Form
1	Zedelmayer, Christine	Sr. Vice President and COO	Direct	Sell	6052026	2.93	14,584	42,737	183,402	Form
2	Connelly, Stephen	President and CSO	Direct	Sell	6052026	2.94	30,975	91,070	2,240,430	Form
3	Connelly, Stephen	President and CSO	Direct	Sell	6052026	3.16	200,000	632,760	2,508,893	Form
4	Tom, Penny	Principal Accounting Officer	Direct	Sell	5292026	2.95	65,000			Form
5	Zedelmayer, Christine	Sr. Vice President and COO	Direct	Sell	5292026	2.80	86,012	240,693	175,138	Form

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Equillium (EQ)

Market Price (9/7/2026): $2.2 | Market Cap: $246.0 MilSector: Health Care | Industry: Biotechnology

Equillium (EQ)

Market Price (9/7/2026): $2.2Market Cap: $246.0 MilSector: Health CareIndustry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

EQ in ETFs

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

In The Past

Preserve Wealth

Asset Allocation

About Equillium (EQ)

Key Risks for Equillium (EQ)

Expected Drivers of Future Revenue Growth for Equillium (EQ) Over the Next 2-3 Years

Interactive Breakdown

Better Bets vs. Equillium (EQ)

Peer Outperformance in Biotechnology

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Top Gainers

Top Losers

Top Gainers

Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

FDA Approved Drugs Data

Clinical Pipeline

Financials

Segment Financials

Price Behavior

Based On 1-Year Data

Based On 5-Year Data

Based On 10-Year Data

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Recent Forward Guidance

Insider Activity

Investor Activity (13F)

EQ Trade Sentinel

null

CONVICTION RATIONALE

STOCK ARCHETYPE

INVESTMENT THESIS

PRIMARY RISK

BULL VIEW

Market Price (9/7/2026): $2.2
Market Cap: $246.0 Mil
Sector: Health Care
Industry: Biotechnology